Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Empirical Formula (Hill Notation):
C21H21FN2O4S
CAS Number:
Molecular Weight:
416.47
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
51111800
MDL number:
Quality Level
assay
≥98% (HPLC)
form
solid
color
white
solubility
DMSO: ≥40 mg/mL, H2O: insoluble
originator
Bayer
storage temp.
2-8°C
SMILES string
OC(=O)CCn1c2CC[C@H](Cc2c3ccccc13)NS(=O)(=O)c4ccc(F)cc4
InChI
1S/C21H21FN2O4S/c22-14-5-8-16(9-6-14)29(27,28)23-15-7-10-20-18(13-15)17-3-1-2-4-19(17)24(20)12-11-21(25)26/h1-6,8-9,15,23H,7,10-13H2,(H,25,26)/t15-/m1/s1
InChI key
LDXDSHIEDAPSSA-OAHLLOKOSA-N
Biochem/physiol Actions
Ramatroban aids in the reduction of myocardial ischemia-reperfusion injury, lipopolysaccharide-induced shock, and vagal neuroeffector transmission in the tracheal smooth muscle of experimental models. In addition, it also suppresses allergen and IgE antibody-mediated skin and nasal reactions and eosinophilia in animal models with asthma.
Ramatroban is used for the treatment of allergic rhinitis as an antagonist of the thromboxane receptor.
Ramatroban is used for the treatment of allergic rhinitis as an antagonist of the thromboxane receptor. It is also an antagonist of the DP2 receptor with IC50 values of 100-170 nM. It is more potent at the DP2 receptor than the TP receptor by 4-5 fold. It is therefore a useful tool for the elucidation of PGD2/DP2 function in eosinophils, basophils, and other cells of the TH2 cell-type.
Features and Benefits
This compound was developed by Bayer. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
signalword
Warning
hcodes
Hazard Classifications
Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3
target_organs
Respiratory system
Storage Class
11 - Combustible Solids
wgk
WGK 1
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
dust mask type N95 (US), Eyeshields, Gloves
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Stéphanie Rolin et al.
European journal of pharmacology, 533(1-3), 89-100 (2006-02-07)
COPD (Chronic Obstructive Pulmonary Disease) and bronchial asthma are two severe lung diseases which represent a major problem of world public health. Leukotrienes and prostanoids play an important role in the pathogenesis of pulmonary diseases. Prostanoids: prostaglandins (PGs) and thromboxane
Petra Schratl et al.
European journal of immunology, 36(9), 2401-2409 (2006-08-15)
Several chemoattractants can regulate the recruitment of eosinophils to sites of inflammation, but the hierarchy among them is unknown. We observed here that eosinophil chemotaxis towards eotaxin or 5-oxo-6,8,11,14-eicosatetraenoic acid (5-oxo-ETE) was amplified up to sixfold in the presence of
Toshiaki Ishizuka et al.
Cardiovascular drug reviews, 22(2), 71-90 (2004-06-05)
It is known that thromboxane A2 (TXA2) contributes to various diseases such as bronchial asthma, ischemic heart disease, cerebrovascular disorders and allergic rhinitis. A number of TXA2 synthase inhibitors and TXA2 receptor (TP receptor) antagonists have been developed to treat
